Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022008316
Abstract: Key Points • In relapsed or refractory AML, mutated NPM1 has no impact on the risk of relapse or death.• The addition of venetoclax to salvage treatment for NPM1-mutated AML is associated with improved outcomes. read more here.
Keywords: refractory aml; clinical outcomes; associated npm1; npm1 mutations ... See more keywords